📊 ESPR Key Takeaways
Is Esperion Therapeutics, Inc. (ESPR) a Good Investment?
Esperion faces a critical financial crisis with negative stockholders' equity of -$302M and liabilities exceeding assets by $302M, indicating technical insolvency. Despite 21.3% revenue growth and positive operating income, the company is burning cash operationally (-$13.1M) and cannot sustain operations without accessing its $167.9M cash reserve, which at current burn rates provides limited runway.
Esperion shows meaningful fundamental improvement, with 21.3% revenue growth, positive operating income, and a sharply narrower net loss, suggesting the commercial model is gaining traction. However, the business still posts negative net income and free cash flow, and the deeply negative equity position with liabilities far above assets materially weakens financial resilience. The fundamentals support cautious monitoring rather than a clearly bullish or bearish stance.
Why Buy Esperion Therapeutics, Inc. Stock? ESPR Key Strengths
- Revenue growth of 21.3% YoY demonstrates market demand for products
- Positive operating income of $60.3M shows core business can generate profits
- Adequate liquidity with $167.9M in cash and 1.54x current ratio provides near-term operational flexibility
- Net loss improved 56.2% YoY indicating losses are narrowing
- Revenue growth remains strong at 21.3% year over year, indicating improving commercial execution
- Operating margin of 15.0% and positive operating income show the core business is now generating operating profit
- Liquidity is still adequate near term, with $167.85M in cash and a 1.54x current ratio
ESPR Stock Risks: Esperion Therapeutics, Inc. Investment Risks
- Negative stockholders' equity of -$302M represents balance sheet insolvency and extreme financial distress
- Negative operating cash flow of -$13.1M indicates the business is not self-sustaining despite positive operating income
- Total liabilities ($767.9M) exceed total assets ($465.9M) by $302M, creating structural balance sheet crisis
- Current cash runway of ~12-13 years at burn rate is inadequate for pharmaceutical company needing R&D investments
- Negative net margin of -5.6% shows company cannot convert revenue to profit at net level despite operating margin of 15%
- Stockholders equity is deeply negative, reflecting an impaired balance sheet and limiting financial flexibility
- Net income and free cash flow remain negative, so the company has not yet demonstrated durable full-cycle profitability
- Total liabilities of $767.85M exceed total assets of $465.89M, creating elevated solvency risk if operating momentum weakens
Key Metrics to Watch
- Path to positive operating cash flow - most critical indicator of sustainability
- Stockholders' equity trajectory - must turn positive to avoid bankruptcy risk
- Cash burn rate relative to cash reserves - determines runway without financing
- Net margin improvement - need to close gap between 15% operating margin and -5.6% net margin
- Revenue growth sustainability - verify if 21.3% growth is maintainable
- Form 4 insider trading activity - 7 filings in 90 days warrant investigation for patterns
- Sustained positive operating cash flow and free cash flow generation
- Net income margin improvement alongside liability reduction and equity stabilization
Esperion Therapeutics, Inc. (ESPR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Esperion Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ESPR Profit Margin, ROE & Profitability Analysis
ESPR vs Healthcare Sector: How Esperion Therapeutics, Inc. Compares
How Esperion Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Esperion Therapeutics, Inc. Stock Overvalued? ESPR Valuation Analysis 2026
Based on fundamental analysis, Esperion Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Esperion Therapeutics, Inc. Balance Sheet: ESPR Debt, Cash & Liquidity
ESPR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Esperion Therapeutics, Inc.'s revenue has grown significantly by 77% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.03 indicates the company is currently unprofitable.
ESPR Revenue Growth, EPS Growth & YoY Performance
ESPR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $51.6M | -$12.7M | $-0.15 |
| Q2 2025 | $73.8M | -$903.0K | $-0.01 |
| Q1 2025 | $65.0M | -$40.5M | $-0.21 |
| Q3 2024 | $34.0M | -$29.5M | $-0.15 |
| Q2 2024 | $25.8M | -$903.0K | $-0.01 |
| Q1 2024 | $24.3M | $61.0M | $0.34 |
| Q3 2023 | $19.0M | -$41.3M | $-0.37 |
| Q2 2023 | $18.8M | -$49.9M | $-0.46 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Esperion Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ESPR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Esperion Therapeutics, Inc. (CIK: 0001434868)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ESPR
What is the AI rating for ESPR?
Esperion Therapeutics, Inc. (ESPR) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 77% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ESPR's key strengths?
Claude: Revenue growth of 21.3% YoY demonstrates market demand for products. Positive operating income of $60.3M shows core business can generate profits. ChatGPT: Revenue growth remains strong at 21.3% year over year, indicating improving commercial execution. Operating margin of 15.0% and positive operating income show the core business is now generating operating profit.
What are the risks of investing in ESPR?
Claude: Negative stockholders' equity of -$302M represents balance sheet insolvency and extreme financial distress. Negative operating cash flow of -$13.1M indicates the business is not self-sustaining despite positive operating income. ChatGPT: Stockholders equity is deeply negative, reflecting an impaired balance sheet and limiting financial flexibility. Net income and free cash flow remain negative, so the company has not yet demonstrated durable full-cycle profitability.
What is ESPR's revenue and growth?
Esperion Therapeutics, Inc. reported revenue of $403.1M.
Does ESPR pay dividends?
Esperion Therapeutics, Inc. does not currently pay dividends.
Where can I find ESPR SEC filings?
Official SEC filings for Esperion Therapeutics, Inc. (CIK: 0001434868) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ESPR's EPS?
Esperion Therapeutics, Inc. has a diluted EPS of $-0.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ESPR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Esperion Therapeutics, Inc. has a SELL rating with 77% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ESPR stock overvalued or undervalued?
Valuation metrics for ESPR: ROE of N/A (sector avg: 15%), net margin of -5.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ESPR stock in 2026?
Our dual AI analysis gives Esperion Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ESPR's free cash flow?
Esperion Therapeutics, Inc.'s operating cash flow is $-13.1M, with capital expenditures of $0.0. FCF margin is -3.2%.
How does ESPR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.54 (avg: 2).